170 likes | 361 Views
Allo -HSCT for ALL. 林建廷. Cancer 2006;106: 2657–63. EBMT: allo -HSCT in ALL. ECOG 2993. ECOG 2993. All pts. Risk stratification at diagnosis. OS. Standard risk. 55%. High risk. 34%. cHR pts. 25%Ph+. 5%. ECOG 2993. ECOG 2993. What happen if relapse? ECOG2993.
E N D
ECOG 2993 All pts Risk stratification at diagnosis OS Standard risk 55% High risk 34% cHR pts 25%Ph+ 5%
MRD and Standard Risk Adult ALL • Germany GMALL group • rt-PCR method, 105 pts in cHR with MRD(-) at enroll • No high WBC, not pro-B, pre-T, mature T, no poor cyt • Median molecular to clinical relapse:9.5m 5/77 (6%) 17/28 (61%) Blood. 2007;109:910-915
RIST for Adult ALL, from EBMT Haematologica 2008 Feb; 93(2):303-306.
RIST for Adult ALL, from EBMT • Retrospective, 97 pts 2-yr Leukemic-free survival Non-relapse mortality Relapse incidence 40%@2yr for CR1 18%@2yr for CR1 52% 42% 18% Haematologica 2008 Feb; 93(2):303-306.
HCT-Comorbidity Index • HCT-CI is 0, and NRM~20%
PAM score is: • 17 if RIST • 20 if myeloablative (non-TBI) • 24 if myeloablative (TBI 12 Gy)